During the conference, Mr. Sapirstein will be available to conduct one-on-one meetings with registered investors, showcasing ...

Nimacimab, a first-in-class CB1-inhibiting monoclonal antibody, is a negative allosteric modulator that acts as both an inverse agonist and antagonist ... income and $4.6 million in income from the ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...